Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Director Joseph L. Goldstein sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $305.93, for a total value of $305,930.00. Following the transaction, the director now owns 11,323 shares in the company, valued at $3,464,045.39. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

REGN traded up $1.23 during trading hours on Wednesday, reaching $305.85. The company’s stock had a trading volume of 733,270 shares, compared to its average volume of 782,783. Regeneron Pharmaceuticals Inc has a fifty-two week low of $291.10 and a fifty-two week high of $442.00. The stock has a market capitalization of $33.35 billion, a PE ratio of 15.45, a P/E/G ratio of 1.44 and a beta of 1.08. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.78 and a current ratio of 4.58.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $4.45 EPS for the quarter, missing analysts’ consensus estimates of $5.24 by ($0.79). Regeneron Pharmaceuticals had a net margin of 35.13% and a return on equity of 26.95%. The business had revenue of $1.71 billion during the quarter, compared to analyst estimates of $1.76 billion. During the same quarter in the prior year, the company posted $4.67 earnings per share. The company’s revenue was up 13.3% on a year-over-year basis. As a group, equities research analysts forecast that Regeneron Pharmaceuticals Inc will post 18.37 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Natixis Advisors L.P. lifted its holdings in Regeneron Pharmaceuticals by 3.7% in the first quarter. Natixis Advisors L.P. now owns 206,398 shares of the biopharmaceutical company’s stock valued at $84,751,000 after acquiring an additional 7,309 shares during the last quarter. MetLife Investment Advisors LLC lifted its holdings in Regeneron Pharmaceuticals by 0.4% in the first quarter. MetLife Investment Advisors LLC now owns 22,283 shares of the biopharmaceutical company’s stock valued at $9,150,000 after acquiring an additional 83 shares during the last quarter. Premia Global Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the first quarter valued at approximately $245,000. Coastal Investment Advisors Inc. acquired a new position in Regeneron Pharmaceuticals in the first quarter valued at approximately $71,000. Finally, Advisors Asset Management Inc. lifted its holdings in Regeneron Pharmaceuticals by 34.2% in the first quarter. Advisors Asset Management Inc. now owns 9,727 shares of the biopharmaceutical company’s stock valued at $3,994,000 after acquiring an additional 2,478 shares during the last quarter. Hedge funds and other institutional investors own 67.63% of the company’s stock.

Several brokerages have recently weighed in on REGN. BidaskClub upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, March 1st. Cantor Fitzgerald restated a “hold” rating and set a $441.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, February 6th. Piper Jaffray Companies boosted their target price on Regeneron Pharmaceuticals to $487.00 and gave the stock an “overweight” rating in a report on Tuesday, February 26th. TheStreet upgraded Regeneron Pharmaceuticals from a “c+” rating to a “b” rating in a report on Thursday, January 17th. Finally, Guggenheim cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $466.00 to $425.00 in a report on Friday, February 22nd. Three investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $404.88.

ILLEGAL ACTIVITY WARNING: “Regeneron Pharmaceuticals Inc (REGN) Director Sells $305,930.00 in Stock” was first reported by Marea Informative and is the property of of Marea Informative. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.mareainformativa.com/news/2019/05/15/regeneron-pharmaceuticals-inc-regn-director-sells-305930-00-in-stock.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

See Also: Dividend Stocks – Are They Right For You?

Insider Buying and Selling by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.